Steven Mickelsen, MD, Launches Del Medtech to Advance Pulsed Field Ablation Beyond Cardiac Applications
[City, State] – September 5, 2025 – PR Newswire Healthring announced today the establishment of Del Medtech, a new company founded by renowned electrophysiologist Steven Mickelsen, MD. This innovative venture is poised to significantly expand the application of pulsed field ablation (PFA) technology beyond its current cardiac uses, opening up new therapeutic avenues for a range of medical conditions.
Pulsed field ablation is a cutting-edge therapeutic modality that utilizes electrical pulses to selectively destroy targeted cells while leaving surrounding healthy tissues unharmed. While PFA has shown remarkable promise in treating cardiac arrhythmias like atrial fibrillation, Del Medtech aims to harness its unique characteristics for a broader spectrum of clinical challenges.
Dr. Steven Mickelsen, a leading figure in the field of electrophysiology and a pioneer in PFA research and development, will lead Del Medtech. His extensive experience and deep understanding of PFA’s biological effects and technological requirements are expected to drive the company’s mission forward.
“We are thrilled to announce the launch of Del Medtech,” stated Dr. Mickelsen. “For years, we have witnessed the transformative potential of pulsed field ablation in cardiology. Our vision with Del Medtech is to meticulously explore and validate how this precision energy source can be safely and effectively applied to treat diseases in other critical organ systems and tissue types. The selectivity of PFA offers a compelling advantage, and we believe its therapeutic reach is far greater than currently realized.”
The strategic focus of Del Medtech will be on rigorous research, development, and clinical validation to establish PFA as a viable and superior treatment option for conditions currently managed with more invasive or less selective methods. This could include applications in areas such as oncology, where precise tumor ablation is paramount, or in the treatment of other non-cardiac tissue-based diseases.
The company’s approach is expected to involve close collaboration with leading clinicians, researchers, and academic institutions to identify unmet clinical needs and translate scientific discoveries into tangible therapeutic solutions. By leveraging existing PFA platform technologies and innovating new delivery systems and protocols, Del Medtech seeks to unlock the full potential of this advanced ablation technique.
The establishment of Del Medtech represents a significant step forward in the evolution of energy-based medical therapies. With Dr. Mickelsen at the helm and a clear strategic direction, the company is well-positioned to make a substantial impact on patient care and expand the therapeutic landscape of pulsed field ablation. Further details regarding specific areas of focus and ongoing research initiatives are anticipated as Del Medtech progresses.
Steven Mickelsen, MD, lance Del Medtech pour étendre l’ablation par champ pulsé au-delà du cœur
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Steven Mickelsen, MD, lance Del Medtech pour étendre l’ablation par champ pulsé au-delà du cœur’ at 2025-09-05 16:46. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.